公开(公告)号：EP4426271A1

公开(公告)日：2024-09-11

申请号：EP22813917.6

申请日：2022-11-02

Applicant: Ziphius Vaccines nv

Inventor： VALEMBOIS, Sophie ,  HAQUE, AKM, Ashiqul ,  SAHU, Itishri ,  MC CAFFERTY, Séan ,  CARDON, Christiaan

IPC: A61K9/51 ,  C07D241/04 ,  A61K47/24 ,  A61K47/22 ,  A61K47/28

CPC classification number: A61K9/5146 ,  A61K47/24 ,  A61K47/22 ,  A61K47/28 ,  C07D295/13

公开(公告)号：EP4420679A2

公开(公告)日：2024-08-28

申请号：EP24169013.0

申请日：2016-06-29

Applicant: Acuitas Therapeutics Inc.

Inventor： DU, Xinyao ,  ANSELL, Steven, M.

IPC: A61K47/18

CPC classification number: C07D295/13 ,  C07C211/09 ,  C07C235/10 ,  A61K9/5123 ,  A61K31/713 ,  A61K31/7105 ,  C07C233/36 ,  C07C233/38 ,  C07D207/09

Abstract: Compounds are provided having the following structure:

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b , R3a , R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, G1, G2, G3, a, b, c and d are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

公开(公告)号：EP4392397A2

公开(公告)日：2024-07-03

申请号：EP22862274.2

申请日：2022-08-25

Applicant: AbbVie Inc.

Inventor： KU, Yi-yin ,  GRIEME, Timothy ,  HARPER, Kaid ,  JIN, Ji-an ,  MACK, Daniel ,  MAREK, James ,  MOSCHETTA, Eric ,  PATEL, Ketan ,  PU, Yu-ming ,  SACIA, Eric ,  TOWNE, Timothy

IPC: C07C17/269 ,  A61K31/03 ,  A61K31/095

CPC classification number: C07C319/14 ,  C07C315/02 ,  C07C317/14 ,  C07D295/13 ,  C07D295/155 ,  C07C51/412

公开(公告)号：EP4384493A1

公开(公告)日：2024-06-19

申请号：EP22855428.3

申请日：2022-08-09

Applicant: Sironax Ltd

Inventor： HOU, Weijie ,  ZHANG, Zhiyuan ,  XU, Yanping ,  JIANG, Yimin ,  XU, Xingyu ,  HAN, Jianguang

IPC: C07C211/44 ,  C07D213/00 ,  C07D231/00 ,  C07D263/00 ,  A61K31/136 ,  A61K31/395 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16

CPC classification number: A61P25/14 ,  A61P25/16 ,  A61P25/00 ,  C07D265/30 ,  C07D241/04 ,  C07D295/13 ,  C07D295/135 ,  C07D401/04 ,  C07D211/58 ,  C07D401/12 ,  C07D405/12 ,  C07D401/14 ,  C07D403/12 ,  C07D211/76 ,  C07D211/56 ,  C07D211/96 ,  C07D211/26 ,  C07D401/06 ,  C07D211/18 ,  C07D211/14 ,  C07D211/22 ,  C07D211/48 ,  C07D211/46 ,  C07D405/14 ,  C07D451/04 ,  C07D487/08 ,  C07D231/12 ,  C07D231/38 ,  C07D213/74 ,  C07D207/14 ,  C07D309/14 ,  C07D207/27 ,  C07D207/277 ,  C07D207/273 ,  C07D205/04 ,  C07D233/32 ,  C07D207/08 ,  C07D215/38 ,  C07D309/04 ,  C07D307/79 ,  C07D277/60 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D233/64 ,  C07D233/61 ,  C07D239/22 ,  C07D335/02 ,  C07D239/47 ,  C07D209/08 ,  C07D267/10 ,  C07D498/08 ,  C07D491/107 ,  C07D491/048 ,  C07F7/0816 ,  C07C2601/1420170501 ,  C07C211/53 ,  C07C217/52 ,  C07C237/24 ,  C07C217/08 ,  C07C2601/0820170501 ,  C07C2601/0420170501 ,  C07C2601/1820170501 ,  C07C215/42 ,  C07C2603/7420170501 ,  C07C2602/0820170501 ,  C07C2602/1020170501 ,  C07C217/84 ,  C07C215/44 ,  C07C2601/0220170501 ,  C07C211/48 ,  C07C229/48 ,  C07C2602/5020170501 ,  C07C215/10 ,  C07C217/90 ,  C07C275/14 ,  C07C275/26 ,  C07C307/08 ,  C07C2602/2220170501 ,  C07C215/16 ,  C07C211/51

公开(公告)号：EP3405183A1

公开(公告)日：2018-11-28

申请号：EP17741793.8

申请日：2017-01-13

Applicant: Arisan Therapeutics Inc.

Inventor： PLEWE, Michael ,  BROWN, Eric ,  GANTLA, Vidyasagar ,  HENKEL, Gregory ,  MCCORMACK, Kenneth ,  SOKOLOVA, Nadezda

IPC: A61K31/015 ,  A61K31/135 ,  A61K31/165 ,  C07C13/28 ,  C07C13/54 ,  C07C13/573

CPC classification number: C07D295/32 ,  A61K31/165 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/407 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4465 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61K31/4995 ,  A61K31/5375 ,  A61K31/551 ,  C07C217/58 ,  C07C233/41 ,  C07C233/43 ,  C07C233/62 ,  C07C235/40 ,  C07C237/24 ,  C07C275/26 ,  C07C2601/14 ,  C07C2603/74 ,  C07D205/04 ,  C07D205/12 ,  C07D209/94 ,  C07D211/34 ,  C07D211/56 ,  C07D211/58 ,  C07D211/60 ,  C07D211/62 ,  C07D213/74 ,  C07D213/75 ,  C07D213/82 ,  C07D233/64 ,  C07D243/08 ,  C07D295/03 ,  C07D295/088 ,  C07D295/13 ,  C07D295/185 ,  C07D295/192 ,  C07D295/26 ,  C07D451/04 ,  C07D453/02 ,  C07D487/04 ,  C07D487/06 ,  C07D487/10

Abstract: Compounds of structural Formula (I) were developed for the treatment of infections by filoviruses including Ebolavirus and Marburgvirus.

公开(公告)号：EP3328368A1

公开(公告)日：2018-06-06

申请号：EP16831462.3

申请日：2016-07-30

Applicant: Taipei Medical University

Inventor： YEN, Yun ,  LIOU, Jing-ping ,  PAN, Shiow-lin

IPC: A61K31/122 ,  C07C50/12

CPC classification number: C07D207/04 ,  A61K31/122 ,  A61K31/166 ,  A61K31/40 ,  A61K31/7048 ,  A61K33/24 ,  A61K45/06 ,  A61P3/10 ,  A61P25/14 ,  A61P25/28 ,  A61P35/00 ,  C07C225/30 ,  C07C235/54 ,  C07C237/34 ,  C07C237/48 ,  C07C255/58 ,  C07C311/29 ,  C07C2602/10 ,  C07D209/08 ,  C07D209/44 ,  C07D213/40 ,  C07D215/38 ,  C07D215/40 ,  C07D295/13 ,  C07D295/135 ,  A61K2300/00

Abstract: The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.

公开(公告)号：EP2646410B1

公开(公告)日：2018-05-16

申请号：EP11845473.5

申请日：2011-07-08

Applicant: Connora Technologies, Inc.

Inventor： PASTINE, Stefan J. ,  LIANG, Bo ,  QIN, Bing

IPC: C07C217/08 ,  C07C217/46 ,  C07C213/06 ,  C07D295/02 ,  C07D295/023 ,  C07D317/08 ,  C08F8/32 ,  C08F8/34

CPC classification number: C08G59/66 ,  C07C217/08 ,  C07C217/84 ,  C07C323/12 ,  C07D295/13 ,  C07D317/08 ,  C08G59/4064 ,  C08G59/50 ,  C08G59/504 ,  C08L63/00

Abstract: Compounds of formula I, uses as crosslinking agents or curing agents thereof, and resins obtained by using the compounds as crosslinking agents.

公开(公告)号：EP3313829A1

公开(公告)日：2018-05-02

申请号：EP16738338.9

申请日：2016-06-29

Applicant: Acuitas Therapeutics Inc.

Inventor： DU, Xinyao ,  ANSELL, Steven, M.

IPC: C07D295/13 ,  C07C211/22 ,  C07C233/36 ,  C07C233/38 ,  C07C235/74 ,  A61K47/18

CPC classification number: C07C233/36 ,  A61K9/145 ,  A61K9/5123 ,  A61K31/7105 ,  A61K31/713 ,  A61K47/18 ,  A61K47/24 ,  C07C211/09 ,  C07C233/38 ,  C07C235/10 ,  C07D207/09 ,  C07D295/13 ,  C12N15/113

Abstract: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, G1, G2, G3, a, b, c and d are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

公开(公告)号：EP3278796A1

公开(公告)日：2018-02-07

申请号：EP17158880.9

申请日：2012-10-26

Applicant: Lumena Pharmaceuticals LLC

Inventor： GEDULIN, Bronislava ,  GREY, Michael ,  O'DONNELL, Niall

IPC: A61K31/155

CPC classification number: C07H13/12 ,  A61K31/155 ,  A61K31/38 ,  A61K31/40 ,  A61K31/4436 ,  A61K31/4453 ,  A61K31/454 ,  A61K31/495 ,  A61K31/4995 ,  A61K31/5377 ,  A61K31/554 ,  A61K31/7028 ,  A61K31/7042 ,  A61K45/06 ,  C07C257/10 ,  C07C279/12 ,  C07D207/04 ,  C07D211/06 ,  C07D211/08 ,  C07D281/10 ,  C07D285/36 ,  C07D295/13 ,  C07D337/08 ,  C07D401/12 ,  C07D413/12 ,  C07D487/08 ,  C07H15/18 ,  C07H15/26 ,  Y02A50/463 ,  A61K2300/00

Abstract: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

Abstract translation: 本文提供了通过向有需要的个体施用治疗有效量的根尖钠依赖性胆汁酸转运蛋白抑制剂（ASBTI）或其药学上可接受的盐来治疗或改善高胆固醇血症或胆汁淤积性肝病的方法。 还提供了用于治疗或改善肝脏疾病，降低血清胆汁酸或肝胆汁酸水平，治疗或改善瘙痒症，减少肝脏酶或减少胆红素的方法，所述方法包括向需要其的个体施用治疗有效量的ASBTI 或其药学上可接受的盐。

公开(公告)号：EP3022179B1

公开(公告)日：2017-11-15

申请号：EP14744009.3

申请日：2014-07-10

Applicant: Fondazione Istituto Italiano Di Tecnologia ,  The Regents of the University of California

Inventor： BOTTEGONI, Giovanni ,  DE SIMONE, Alessio ,  RUDA, Gian Filippo ,  CAVALLI, Andrea ,  BANDIERA, Tiziano ,  PIOMELLI, Daniele

IPC: C07D209/88 ,  C07D211/38 ,  C07D213/30 ,  C07D295/125 ,  C07D295/13 ,  A61K31/495 ,  A61K31/496 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/30 ,  C07D211/14

CPC classification number: C07D295/13 ,  C07D209/88 ,  C07D211/14 ,  C07D211/38 ,  C07D213/30 ,  C07D295/125

Abstract: The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof wherein Ar′, R1, R2, R3, R4, X, Y are as defined in the description of invention, as multi-target directed ligands (MTDLs) that are at the same time inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR), their methods of preparation, formulations and therapeutic applications thereof.